×
About 341,680 results

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
https://clinicaltrials.gov/ct2/show/NCT03486873

Mar 17th, 2023 - The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one...

Defining Neurobiological Links Between Substance Use and Mental Illness
https://clinicaltrials.gov/ct2/show/NCT05538910

Mar 17th, 2023 - Study Description: Tobacco smoking leads to 480,000 deaths and a loss of $300 billion a year in the U.S. Individuals with major depressive disorder (MDD) are more vulnerable for experiencing these burdens as they are twice as likely to use nicotine versus the general population. The current work will explain the neurobiological basis of this enhanced risk and will define potential targets for l...

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
https://clinicaltrials.gov/ct2/show/NCT05538897

Mar 17th, 2023 - PRIMARY OBJECTIVES: I. Determine the toxicity of ipatasertib in combination with megestrol acetate in women with metastatic grade 1-2 endometrioid endometrial cancer and establish the recommended phase II dose. (Phase I) II. Compare the progression free survival of the combination of ipatasertib with megestrol acetate to megestrol acetate alone among women with metastatic grade 1-2 endometrioid...

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04616196

Mar 17th, 2023 - NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects. In the dose escalation (Phase 1/b) phase patients with HNSCC or CRC will be treated with ascending doses of NKTR-255 in combination with cetuximab, until the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) is reached. The recommend...

An "All-Comers" Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients
https://clinicaltrials.gov/ct2/show/NCT04085445

Mar 16th, 2023 - The Agent DCB Registry study will enroll 500 subjects at up to 10 investigational sites in Taiwan, Hong-Kong and Singapore. If participants decide to participate in this study, participants will first be asked to sign and date this consent form. If participants sign the consent form, participants will go through a baseline/ procedure process. Information about participants and participants' hea...

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02778685

Mar 16th, 2023 - PRIMARY OBJECTIVES: I. To evaluate the objective response rate (ORR), based on Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), of pembrolizumab in combination with letrozole and palbociclib in patients with newly diagnosed metastatic estrogen receptor (ER) positive (+) human epidermal growth factor receptor (HER)2 negative (-) breast cancer, and determine if the addition of ...

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
https://clinicaltrials.gov/ct2/show/NCT04608630

Mar 16th, 2023 - Intensive care patients face health issues that extend beyond their critical illness. A specific area where critical illness may adversely affect the well-being of survivors is increased bone turnover during critical illness, and accelerated bone loss in subsequent years. Critical illness bone loss begins in the first days of critical illness, occurs in both men and women, and is greatest in po...

Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
https://clinicaltrials.gov/ct2/show/NCT04189107

Mar 16th, 2023 - The morbidity after TORS has not yet been fully investigated, but a recent studies suggest that pain is one of the primary causes for unplanned readmission This issue has been investigated by Clayburgh D et al who found that a prolonged dexamethasone regime lowered the pain scores on day three after surgery. The patients treated with the prolonged dexamethasone regime also showed a significant ...

An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
https://clinicaltrials.gov/ct2/show/NCT04616807

Mar 16th, 2023 - This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM. Namuscla should be prescribed as per the approved Summary of Product Characteristics (SmPC). Adult patients with non-dystrophic myotonic disorders who have been prescribed Namuscla by the treating physician, and who meet the eligi...

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
https://clinicaltrials.gov/ct2/show/NCT04603183

Mar 16th, 2023 - The ABIGAIL study aims to provide consistent evidence that the combination of abemaciclib with ET -consisting of letrozole or fulvestrant-as first-line regimen is non-inferior to the optimal first-line chemotherapy -consisting of weekly paclitaxel-in terms of early ORR after the first 12 weeks of treatment in patients with HR-positive/HER2-negative ABC and at least one feature of aggressive dis...

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
https://clinicaltrials.gov/ct2/show/NCT05483933

Mar 15th, 2023 - Study SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate the safety, pharmacokinetics, pharmacodynamic effects, and preliminary anti-tumor activity of SL-172154 administered in combination with either PLD or MIRV in subjects with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Patients will be appropriate for combination therapy for their ...

Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries
https://clinicaltrials.gov/ct2/show/NCT05543785

Mar 15th, 2023 - This is a randomized controlled trial that tests the effecacy of the intravenous regional ketorolac in lower limb orthopedic surgeries with spinal anesthesia. The investigators will compare the effect of 30 mg ketorolac without local anesthetic in the injected intravenously in an isolated lower limb (with torniquet) versus intravenous 30 mg ketorolac administered 10 minutes before toniquet pres...

Investigational and Comparative Study in the Management of Diabetic Nephropathy
https://clinicaltrials.gov/ct2/show/NCT05487755

Mar 15th, 2023 - Diabetic nephropathy(DN) is one of the major micro- vascular complications of diabetes mellitus and the leading cause of end-stage renal disease (ESRD) that require renal replacement therapies. The average incidence of diabetic nephropathy is 3% per year during the first 10 to 20 years after diabetes onset. Diabetic nephropathy occurs in 20-40% of all diabetic patients. Pathogenesis of diabetic...

Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy
https://clinicaltrials.gov/ct2/show/NCT04182997

Mar 15th, 2023 - Intraoperative epidural administration of steroids following discectomy for herniated lumbar disc has been the topic of multiple studies in the literature. The results have been mixed, with the majority of the studies finding some benefit, but outcomes have varied drastically amongst the many studies. The aim of this study is to develop a grading scale for intraoperative assessment of nerve roo...

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT04616183

Mar 15th, 2023 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ERK1/2 inhibitor LY3214996 (LY3214996) administered in combination with cetuximab. (Phase 1b) II. Determine the MTD and RP2D of LY3214996 administered in combination with cetuximab plus abemaciclib. (Phase 1b) III. Assess the preliminary antitumor activity of the treatment combinations based...

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema
https://clinicaltrials.gov/ct2/show/NCT00309192

Mar 14th, 2023 - Diabetes mellitus and its complications represent nowadays an important issue in Public Health terms. The WHO expectations indicate that around 2025 the European population with diabetes will reach about 12%, and it has been estimated that the percent in the USA will be around 10% (King, 1995). The severe complications of proliferant diabetic retinopathy and its disastrous effects on vision see...

The Effect of NAD Supplementation on Brain Vascular Health in Aging
https://clinicaltrials.gov/ct2/show/NCT05483465

Mar 14th, 2023 - This study is designed to test the hypothesis that restoration of Nicotinamide Adenine Dinucleotide (NAD) levels with Nicotinamide Riboside (NR) in older adults will improve neurovascular coupling (NVC) responses and micro- and macrovascular endothelial function. This hypothesis will be tested by assessing the effects of treatment with oral NR (1g/day per os for 8 weeks) or placebo (8 weeks) in...

Capsaicin for Cerebral Perfusion Augmentation
https://clinicaltrials.gov/ct2/show/NCT05543837

Mar 14th, 2023 - Subjects The study is expected to enroll 30 participants who will be recruited from the Internal Medicine outpatient clinic. Those willing to participate will be asked to sign the informed consent form (ICF) and will received the assigned dose of capsaicin. Half of the participants in each dose group will receive stimulation on either left or right side of the palate, but TCD measurements will ...

Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee
https://clinicaltrials.gov/ct2/show/NCT05486026

Mar 14th, 2023 - This will be a 13-week A randomized open labelled clinical trail in Iraqi Kurdistan Region, that will be designed to assess the efficacy of duloxetine tablet compared with other group (Nonsteroidal anti-inflammatory) drug on the reduction of pain caused by osteoarthritis of the knee. Patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks t...

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
https://clinicaltrials.gov/ct2/show/NCT04643002

Mar 14th, 2023 - Approximately 28 months